biologic

Aduhelm

aducanumab-avwa

Loss of exclusivityJune 2033projected — 12-year biologic exclusivity estimate
CompanyBiogenView the full company profile on CliffBio

Drug detail

Brand nameAduhelm
Active ingredientaducanumab-avwa
Strength300MG/3ML (100MG/ML)
Dosage formInjection
RouteIntravenous
ModalityBiologic
FDA approvalJune 2021
Marketing statusRx

Source: FDA Purple Book, layered on the CliffBio company graph. Cliff dates are the projected — 12-year biologic exclusivity estimate; estimates are projections, not legal advice.

Not found